Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer

Published on 04 Jan 2022
Last Updated on 04 Jan 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Dabrafenib 50 mg and 75 mg capsules in combination with trametinib 0.5 mg and 2 mg tablets for treating locally advanced or metastatic anaplastic thyroid cancer in patients with a BRAF V600 mutation and with no satisfactory locoregional treatment options.

Subsidy status

Dabrafenib 50 mg and 75 mg capsules and trametinib 0.5 mg and 2 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 4 January 2022.

Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.

Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer (4 Jan 2022) [PDF, 123 KB]

PES Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer (Published 4 Jan 2022) [PDF, 90 KB]